About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGNA

Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever

Early Versus Late Stopping of Antibiotics in Adults With High Risk Haematological Malignancies/Receiving Cellular Therapies and Fever (ELSA- Adult)

NCT07051525•Peter MacCallum Cancer Centre, Australia

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

LeukemiaCART TherapyTransplantation, Stem Cell+1 more

Interventions

Early antibiotic cessation alert

Locations

2

Australia

Locations (2)

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Key Dates

Start Date

December 3, 2025

Primary Completion Date

December 5, 2027

Completion Date

February 5, 2028

Last Updated

December 15, 2025

Related Studies

RECRUITINGEARLY Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690

Acute Lymphoblastic Leukemia

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014

Non-Hodgkin's LymphomaHodgkin's Disease+2 more

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+3 more

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

NCT06074666

Acute Lymphoblastic Leukemia, Pediatric

RECRUITINGPhase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671

CLLChronic Lymphocytic Leukemia

View all related studies

Contacts

Principal Investigator

CONTACT

+61448503643 infectiousdiseases.clinicaltrials@petermac.org

Sponsors

Lead Sponsor

Peter MacCallum Cancer Centre, Australia

Collaborators

Melbourne Health

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions